| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 25 | 2024 | 175 | 5.160 |
Why?
|
| Embolization, Therapeutic | 28 | 2022 | 262 | 4.250 |
Why?
|
| Thrombectomy | 13 | 2023 | 172 | 3.720 |
Why?
|
| Angiography, Digital Subtraction | 17 | 2024 | 99 | 3.500 |
Why?
|
| Stents | 23 | 2022 | 395 | 3.450 |
Why?
|
| Cerebral Angiography | 25 | 2019 | 197 | 3.410 |
Why?
|
| Endovascular Procedures | 24 | 2024 | 270 | 3.360 |
Why?
|
| Intracranial Arteriovenous Malformations | 14 | 2022 | 109 | 3.270 |
Why?
|
| Stroke | 23 | 2023 | 982 | 3.050 |
Why?
|
| Magnetic Resonance Angiography | 18 | 2024 | 271 | 2.770 |
Why?
|
| Cerebrovascular Disorders | 10 | 2019 | 143 | 2.510 |
Why?
|
| Intracranial Arteriosclerosis | 8 | 2024 | 55 | 2.490 |
Why?
|
| Brain Ischemia | 10 | 2023 | 399 | 2.280 |
Why?
|
| Cerebrovascular Circulation | 11 | 2023 | 227 | 1.930 |
Why?
|
| Neuroimaging | 6 | 2019 | 117 | 1.700 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2024 | 3443 | 1.590 |
Why?
|
| Arteriovenous Fistula | 8 | 2016 | 53 | 1.580 |
Why?
|
| Imaging, Three-Dimensional | 11 | 2019 | 595 | 1.560 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2024 | 59 | 1.440 |
Why?
|
| Computed Tomography Angiography | 4 | 2018 | 146 | 1.180 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2018 | 98 | 1.100 |
Why?
|
| Retrospective Studies | 35 | 2024 | 9003 | 1.090 |
Why?
|
| Contrast Media | 9 | 2024 | 1090 | 1.060 |
Why?
|
| Humans | 132 | 2024 | 89073 | 1.050 |
Why?
|
| Middle Aged | 54 | 2024 | 25865 | 1.050 |
Why?
|
| Treatment Outcome | 40 | 2024 | 8203 | 1.050 |
Why?
|
| Reperfusion | 4 | 2020 | 32 | 1.040 |
Why?
|
| Carotid Artery Diseases | 4 | 2019 | 98 | 1.040 |
Why?
|
| Polyvinyls | 5 | 2013 | 17 | 1.040 |
Why?
|
| Male | 76 | 2024 | 42254 | 1.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2020 | 38 | 1.020 |
Why?
|
| Aged | 42 | 2024 | 19078 | 1.010 |
Why?
|
| Female | 73 | 2024 | 46014 | 0.940 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2024 | 2657 | 0.940 |
Why?
|
| Vasculitis | 1 | 2024 | 40 | 0.940 |
Why?
|
| Aneurysm, Ruptured | 9 | 2024 | 54 | 0.890 |
Why?
|
| Blood Vessel Prosthesis | 7 | 2021 | 242 | 0.860 |
Why?
|
| Vasospasm, Intracranial | 3 | 2011 | 35 | 0.850 |
Why?
|
| Hemodynamics | 7 | 2023 | 729 | 0.810 |
Why?
|
| Catheterization | 3 | 2019 | 237 | 0.800 |
Why?
|
| Arteriovenous Malformations | 2 | 2013 | 45 | 0.780 |
Why?
|
| After-Hours Care | 1 | 2021 | 8 | 0.760 |
Why?
|
| Atherosclerosis | 1 | 2024 | 256 | 0.750 |
Why?
|
| Neurosurgical Procedures | 7 | 2021 | 232 | 0.730 |
Why?
|
| Adult | 42 | 2024 | 26508 | 0.710 |
Why?
|
| Time-to-Treatment | 2 | 2021 | 112 | 0.710 |
Why?
|
| Cerebral Arteries | 6 | 2017 | 75 | 0.710 |
Why?
|
| Radiography, Interventional | 3 | 2010 | 154 | 0.700 |
Why?
|
| Intracranial Hemorrhages | 2 | 2018 | 129 | 0.700 |
Why?
|
| Vertebral Artery | 3 | 2016 | 24 | 0.670 |
Why?
|
| Neutrophils | 1 | 2020 | 308 | 0.650 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2021 | 143 | 0.630 |
Why?
|
| Lymphocytes | 1 | 2020 | 471 | 0.620 |
Why?
|
| Polymers | 2 | 2021 | 194 | 0.620 |
Why?
|
| Catheters | 1 | 2018 | 76 | 0.610 |
Why?
|
| Aneurysm, False | 2 | 2024 | 54 | 0.590 |
Why?
|
| Carotid Stenosis | 4 | 2022 | 115 | 0.590 |
Why?
|
| Gadolinium | 2 | 2016 | 103 | 0.570 |
Why?
|
| Carotid Artery, Internal | 3 | 2016 | 68 | 0.570 |
Why?
|
| Sensitivity and Specificity | 12 | 2019 | 2014 | 0.560 |
Why?
|
| Carotid Artery, Internal, Dissection | 3 | 2014 | 22 | 0.560 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2020 | 138 | 0.540 |
Why?
|
| Spinal Cord | 3 | 2014 | 255 | 0.540 |
Why?
|
| Pseudotumor Cerebri | 1 | 2016 | 17 | 0.540 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 1063 | 0.530 |
Why?
|
| Radiation Exposure | 1 | 2016 | 24 | 0.530 |
Why?
|
| Radiation Dosage | 2 | 2016 | 225 | 0.530 |
Why?
|
| Tinnitus | 1 | 2016 | 21 | 0.530 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2015 | 19 | 0.520 |
Why?
|
| Perfusion Imaging | 2 | 2018 | 50 | 0.520 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 162 | 0.520 |
Why?
|
| Reproducibility of Results | 13 | 2023 | 2752 | 0.510 |
Why?
|
| Brain | 8 | 2023 | 2281 | 0.510 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 6777 | 0.500 |
Why?
|
| Burnout, Professional | 3 | 2022 | 100 | 0.490 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2017 | 63 | 0.490 |
Why?
|
| Cerebral Revascularization | 2 | 2014 | 28 | 0.490 |
Why?
|
| Vascular Surgical Procedures | 3 | 2009 | 149 | 0.450 |
Why?
|
| Cranial Sinuses | 3 | 2021 | 15 | 0.440 |
Why?
|
| Physicians | 5 | 2022 | 689 | 0.430 |
Why?
|
| Vertebral Artery Dissection | 2 | 2014 | 13 | 0.430 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.430 |
Why?
|
| Image Enhancement | 5 | 2019 | 567 | 0.400 |
Why?
|
| Carotid Body Tumor | 1 | 2011 | 3 | 0.390 |
Why?
|
| Endarterectomy, Carotid | 2 | 2022 | 75 | 0.390 |
Why?
|
| Risk Factors | 10 | 2022 | 5466 | 0.390 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 13 | 0.380 |
Why?
|
| Microsurgery | 2 | 2023 | 88 | 0.380 |
Why?
|
| Fibrinolytic Agents | 5 | 2018 | 214 | 0.370 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 36 | 0.370 |
Why?
|
| Hydroxyapatites | 1 | 2010 | 7 | 0.360 |
Why?
|
| Molar | 1 | 2010 | 22 | 0.360 |
Why?
|
| Blood Flow Velocity | 8 | 2023 | 198 | 0.360 |
Why?
|
| Oral Surgical Procedures | 1 | 2010 | 19 | 0.360 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 25 | 0.360 |
Why?
|
| Hemorrhage | 2 | 2014 | 278 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1043 | 0.350 |
Why?
|
| Carotid Artery Injuries | 1 | 2010 | 22 | 0.350 |
Why?
|
| Young Adult | 10 | 2021 | 6289 | 0.340 |
Why?
|
| Diagnosis, Differential | 7 | 2015 | 1591 | 0.340 |
Why?
|
| Algorithms | 4 | 2023 | 1875 | 0.340 |
Why?
|
| Central Nervous System Vascular Malformations | 4 | 2018 | 33 | 0.340 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3657 | 0.330 |
Why?
|
| Job Satisfaction | 2 | 2020 | 76 | 0.330 |
Why?
|
| Intracranial Thrombosis | 2 | 2018 | 27 | 0.330 |
Why?
|
| Mandible | 1 | 2010 | 120 | 0.320 |
Why?
|
| Collateral Circulation | 2 | 2020 | 35 | 0.320 |
Why?
|
| Postoperative Complications | 7 | 2023 | 2275 | 0.320 |
Why?
|
| Prospective Studies | 8 | 2023 | 4273 | 0.320 |
Why?
|
| Radiosurgery | 3 | 2022 | 280 | 0.310 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2021 | 226 | 0.310 |
Why?
|
| Research Report | 2 | 2021 | 44 | 0.310 |
Why?
|
| Angioplasty | 3 | 2021 | 70 | 0.310 |
Why?
|
| Registries | 3 | 2023 | 778 | 0.300 |
Why?
|
| Pilot Projects | 6 | 2023 | 865 | 0.300 |
Why?
|
| Dimethyl Sulfoxide | 3 | 2013 | 38 | 0.300 |
Why?
|
| Adolescent | 13 | 2021 | 9237 | 0.300 |
Why?
|
| Anticoagulants | 3 | 2024 | 426 | 0.300 |
Why?
|
| Eye Diseases | 2 | 2005 | 58 | 0.300 |
Why?
|
| Surgical Flaps | 1 | 2010 | 249 | 0.290 |
Why?
|
| Diagnostic Imaging | 3 | 2009 | 479 | 0.290 |
Why?
|
| Hand | 5 | 1991 | 133 | 0.290 |
Why?
|
| Single-Blind Method | 3 | 2018 | 150 | 0.280 |
Why?
|
| Prevalence | 4 | 2021 | 1240 | 0.280 |
Why?
|
| Cerebral Veins | 3 | 2016 | 31 | 0.270 |
Why?
|
| Pandemics | 3 | 2021 | 771 | 0.270 |
Why?
|
| Rotavirus | 3 | 1991 | 11 | 0.270 |
Why?
|
| Risk Assessment | 6 | 2022 | 2291 | 0.270 |
Why?
|
| Neurosurgery | 3 | 2020 | 99 | 0.270 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2023 | 685 | 0.270 |
Why?
|
| Societies, Medical | 3 | 2021 | 570 | 0.260 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2017 | 18 | 0.250 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2005 | 1 | 0.250 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 3 | 2009 | 4 | 0.250 |
Why?
|
| Orbital Neoplasms | 1 | 2005 | 17 | 0.250 |
Why?
|
| Lacrimal Apparatus | 1 | 2005 | 11 | 0.250 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 27 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.250 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 304 | 0.250 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 2612 | 0.250 |
Why?
|
| Gadolinium DTPA | 2 | 2024 | 264 | 0.250 |
Why?
|
| Hirudins | 1 | 2024 | 5 | 0.240 |
Why?
|
| Hemangioma, Cavernous | 1 | 2005 | 69 | 0.240 |
Why?
|
| Eye | 1 | 2005 | 111 | 0.240 |
Why?
|
| Radiology, Interventional | 3 | 2009 | 69 | 0.240 |
Why?
|
| Antithrombins | 1 | 2024 | 16 | 0.240 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2020 | 302 | 0.240 |
Why?
|
| Multimorbidity | 1 | 2024 | 5 | 0.230 |
Why?
|
| National Health Programs | 1 | 2024 | 19 | 0.230 |
Why?
|
| Fatal Outcome | 2 | 2016 | 299 | 0.230 |
Why?
|
| Medicare | 2 | 2018 | 423 | 0.230 |
Why?
|
| Treatment Failure | 2 | 2021 | 287 | 0.220 |
Why?
|
| Heparin | 1 | 2024 | 185 | 0.220 |
Why?
|
| Propensity Score | 1 | 2023 | 147 | 0.220 |
Why?
|
| Phantoms, Imaging | 4 | 2019 | 448 | 0.220 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 187 | 0.210 |
Why?
|
| Artifacts | 4 | 2013 | 245 | 0.210 |
Why?
|
| Elective Surgical Procedures | 2 | 2021 | 126 | 0.210 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2015 | 141 | 0.210 |
Why?
|
| Time Factors | 7 | 2021 | 5320 | 0.210 |
Why?
|
| Delivery of Health Care | 3 | 2024 | 435 | 0.200 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 1012 | 0.200 |
Why?
|
| Peptide Fragments | 1 | 2024 | 463 | 0.200 |
Why?
|
| Carotid Arteries | 2 | 2021 | 127 | 0.200 |
Why?
|
| Cohort Studies | 9 | 2023 | 2863 | 0.190 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2021 | 11 | 0.190 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 198 | 0.190 |
Why?
|
| Child | 10 | 2021 | 7149 | 0.190 |
Why?
|
| Embolic Protection Devices | 1 | 2021 | 9 | 0.190 |
Why?
|
| Embolism | 1 | 2021 | 32 | 0.190 |
Why?
|
| Hospitals, Community | 1 | 2021 | 32 | 0.190 |
Why?
|
| Neurosurgeons | 1 | 2021 | 32 | 0.190 |
Why?
|
| Hand Disinfection | 2 | 1991 | 17 | 0.190 |
Why?
|
| Hydralazine | 1 | 2020 | 19 | 0.190 |
Why?
|
| North America | 1 | 2021 | 184 | 0.180 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 8 | 0.180 |
Why?
|
| Acute Disease | 2 | 2014 | 841 | 0.180 |
Why?
|
| Neck | 2 | 2013 | 103 | 0.180 |
Why?
|
| Patient Readmission | 2 | 2022 | 351 | 0.180 |
Why?
|
| Observer Variation | 4 | 2016 | 610 | 0.180 |
Why?
|
| United States | 11 | 2022 | 6957 | 0.180 |
Why?
|
| Thoracic Vertebrae | 1 | 2020 | 51 | 0.180 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 385 | 0.180 |
Why?
|
| Basilar Artery | 1 | 2020 | 42 | 0.180 |
Why?
|
| Emergencies | 1 | 2021 | 121 | 0.180 |
Why?
|
| Conservative Treatment | 1 | 2020 | 21 | 0.180 |
Why?
|
| Norepinephrine | 1 | 2020 | 170 | 0.180 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 232 | 0.180 |
Why?
|
| Permeability | 2 | 2017 | 137 | 0.170 |
Why?
|
| Hydrogels | 1 | 2020 | 86 | 0.170 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 29 | 0.170 |
Why?
|
| Lumbar Vertebrae | 1 | 2020 | 151 | 0.170 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 66 | 0.170 |
Why?
|
| Social Media | 1 | 2021 | 93 | 0.160 |
Why?
|
| Computer Graphics | 1 | 2019 | 100 | 0.160 |
Why?
|
| Health Expenditures | 2 | 2018 | 91 | 0.160 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2013 | 251 | 0.160 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2011 | 30 | 0.160 |
Why?
|
| Embolectomy | 2 | 2015 | 6 | 0.160 |
Why?
|
| Physician's Role | 1 | 2020 | 177 | 0.160 |
Why?
|
| Preoperative Care | 2 | 2012 | 396 | 0.160 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 783 | 0.160 |
Why?
|
| Angiography | 3 | 2020 | 208 | 0.160 |
Why?
|
| Vascular Closure Devices | 1 | 2018 | 3 | 0.160 |
Why?
|
| Multimodal Imaging | 2 | 2017 | 111 | 0.160 |
Why?
|
| Chicago | 2 | 2021 | 1423 | 0.160 |
Why?
|
| Spinal Diseases | 2 | 2020 | 44 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1706 | 0.150 |
Why?
|
| Neuroendoscopy | 1 | 2018 | 18 | 0.150 |
Why?
|
| Intracranial Hypertension | 2 | 2016 | 57 | 0.150 |
Why?
|
| Disease Management | 2 | 2017 | 329 | 0.150 |
Why?
|
| Health Personnel | 1 | 2020 | 212 | 0.150 |
Why?
|
| Escherichia coli | 2 | 1991 | 605 | 0.150 |
Why?
|
| Foreign Bodies | 1 | 2018 | 66 | 0.150 |
Why?
|
| Neurovascular Coupling | 1 | 2017 | 2 | 0.150 |
Why?
|
| Thrombosis | 1 | 2020 | 302 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 1239 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 60 | 0.140 |
Why?
|
| Pia Mater | 1 | 2016 | 5 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2019 | 265 | 0.140 |
Why?
|
| Superior Sagittal Sinus | 1 | 2016 | 2 | 0.140 |
Why?
|
| Patient Selection | 3 | 2021 | 682 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 412 | 0.140 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 72 | 0.140 |
Why?
|
| Arteriosclerosis | 1 | 2016 | 112 | 0.130 |
Why?
|
| Veins | 1 | 2016 | 95 | 0.130 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2016 | 67 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2023 | 850 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2016 | 131 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1710 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 643 | 0.130 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 781 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1855 | 0.120 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 11 | 0.120 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 109 | 0.120 |
Why?
|
| Capillary Permeability | 1 | 2015 | 130 | 0.120 |
Why?
|
| Thromboembolism | 2 | 2014 | 120 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 249 | 0.120 |
Why?
|
| Radiography | 2 | 2013 | 809 | 0.120 |
Why?
|
| Hoarseness | 1 | 2013 | 11 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 491 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1755 | 0.110 |
Why?
|
| Vocal Cord Paralysis | 1 | 2013 | 27 | 0.110 |
Why?
|
| Syndrome | 2 | 2011 | 449 | 0.110 |
Why?
|
| Moyamoya Disease | 1 | 2013 | 16 | 0.110 |
Why?
|
| Platinum | 2 | 2020 | 63 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 377 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2015 | 168 | 0.110 |
Why?
|
| Fistula | 1 | 2013 | 42 | 0.110 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 463 | 0.110 |
Why?
|
| Vertebroplasty | 1 | 2013 | 8 | 0.110 |
Why?
|
| Needles | 1 | 2013 | 36 | 0.110 |
Why?
|
| Ventriculostomy | 1 | 2013 | 28 | 0.110 |
Why?
|
| Competency-Based Education | 1 | 2013 | 36 | 0.110 |
Why?
|
| Illinois | 1 | 2014 | 472 | 0.100 |
Why?
|
| Aortic Coarctation | 1 | 2012 | 36 | 0.100 |
Why?
|
| Astrocytoma | 1 | 2012 | 82 | 0.100 |
Why?
|
| Paramyxoviridae Infections | 1 | 1991 | 5 | 0.100 |
Why?
|
| Common Cold | 1 | 1991 | 13 | 0.100 |
Why?
|
| Disinfection | 1 | 1991 | 15 | 0.100 |
Why?
|
| Rotavirus Infections | 1 | 1991 | 12 | 0.100 |
Why?
|
| Hemostasis | 1 | 2011 | 21 | 0.100 |
Why?
|
| Gastroenteritis | 1 | 1991 | 26 | 0.090 |
Why?
|
| Length of Stay | 3 | 2015 | 732 | 0.090 |
Why?
|
| Injections | 1 | 2011 | 116 | 0.090 |
Why?
|
| Aging | 1 | 2016 | 716 | 0.090 |
Why?
|
| Iatrogenic Disease | 1 | 2011 | 70 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 125 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 1991 | 106 | 0.090 |
Why?
|
| Postpartum Period | 1 | 2011 | 144 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1715 | 0.090 |
Why?
|
| Headache | 1 | 2011 | 72 | 0.090 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 22 | 0.090 |
Why?
|
| Alveolar Bone Loss | 1 | 2010 | 20 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2021 | 3717 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 1991 | 154 | 0.090 |
Why?
|
| Survival Rate | 1 | 2014 | 1889 | 0.090 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1989 | 23 | 0.090 |
Why?
|
| Recurrence | 3 | 2020 | 1140 | 0.090 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2009 | 7 | 0.090 |
Why?
|
| Hospitalization | 1 | 2015 | 876 | 0.090 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 2009 | 3 | 0.080 |
Why?
|
| Hemostatics | 1 | 2009 | 57 | 0.080 |
Why?
|
| Iohexol | 1 | 2009 | 25 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2010 | 187 | 0.080 |
Why?
|
| Cerebrovascular Trauma | 1 | 2009 | 8 | 0.080 |
Why?
|
| Neuroradiography | 1 | 2008 | 3 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 234 | 0.080 |
Why?
|
| Incidence | 3 | 2020 | 1592 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 1988 | 23 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 73 | 0.080 |
Why?
|
| Infant | 4 | 2016 | 3147 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1488 | 0.080 |
Why?
|
| Critical Illness | 1 | 2011 | 306 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2021 | 386 | 0.080 |
Why?
|
| Mass Screening | 1 | 2013 | 636 | 0.080 |
Why?
|
| Anesthesia | 1 | 2010 | 169 | 0.080 |
Why?
|
| Head | 1 | 2008 | 135 | 0.070 |
Why?
|
| Dogs | 2 | 2020 | 704 | 0.070 |
Why?
|
| Anesthesiology | 1 | 2010 | 161 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 338 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1837 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2009 | 164 | 0.070 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2006 | 31 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 521 | 0.070 |
Why?
|
| Inpatients | 2 | 2022 | 310 | 0.070 |
Why?
|
| Aneurysm | 2 | 2017 | 60 | 0.060 |
Why?
|
| ROC Curve | 2 | 2019 | 781 | 0.060 |
Why?
|
| Neurologic Examination | 2 | 2016 | 120 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 26 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2006 | 235 | 0.060 |
Why?
|
| Australia | 1 | 2024 | 101 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1212 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2476 | 0.050 |
Why?
|
| Spine | 2 | 2013 | 102 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 166 | 0.050 |
Why?
|
| Equipment Design | 2 | 2018 | 415 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2015 | 779 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 179 | 0.050 |
Why?
|
| Medical Errors | 1 | 2022 | 117 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2022 | 98 | 0.050 |
Why?
|
| Sleep Deprivation | 1 | 2022 | 138 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 257 | 0.050 |
Why?
|
| Infarction | 1 | 2020 | 27 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 1097 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2024 | 948 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 56 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 108 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 146 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1867 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 114 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 63 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 742 | 0.040 |
Why?
|
| Calcinosis | 1 | 2019 | 230 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 143 | 0.040 |
Why?
|
| Decision Making | 1 | 2023 | 665 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 178 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 308 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2019 | 243 | 0.040 |
Why?
|
| Urban Health Services | 1 | 2017 | 45 | 0.040 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2017 | 20 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2018 | 118 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 30 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 128 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2016 | 20 | 0.030 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 16 | 0.030 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2016 | 14 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 149 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 202 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2016 | 47 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 216 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2015 | 57 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 2015 | 66 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 217 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 104 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 107 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 705 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 988 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1528 | 0.030 |
Why?
|
| Shear Strength | 1 | 2013 | 18 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 296 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1067 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 232 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 83 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2017 | 575 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2013 | 106 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2013 | 60 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 682 | 0.030 |
Why?
|
| Animals | 4 | 2020 | 27324 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 80 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2013 | 122 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 253 | 0.030 |
Why?
|
| Software | 1 | 2017 | 665 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2013 | 176 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2013 | 53 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1063 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 833 | 0.030 |
Why?
|
| Magnetic Fields | 1 | 2012 | 11 | 0.030 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 1991 | 2 | 0.030 |
Why?
|
| Disinfectants | 1 | 1991 | 8 | 0.030 |
Why?
|
| Rhinovirus | 1 | 1991 | 25 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 292 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 157 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 187 | 0.020 |
Why?
|
| Air Microbiology | 1 | 1991 | 5 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2013 | 121 | 0.020 |
Why?
|
| Water Microbiology | 1 | 1991 | 13 | 0.020 |
Why?
|
| Michigan | 1 | 2010 | 53 | 0.020 |
Why?
|
| Pain | 1 | 2013 | 400 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 225 | 0.020 |
Why?
|
| Soaps | 1 | 1989 | 2 | 0.020 |
Why?
|
| Fresh Water | 1 | 1989 | 20 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 433 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 434 | 0.020 |
Why?
|
| Seasons | 1 | 1991 | 237 | 0.020 |
Why?
|
| Global Health | 1 | 1991 | 186 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2009 | 27 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1149 | 0.020 |
Why?
|
| Craniotomy | 1 | 2010 | 88 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2362 | 0.020 |
Why?
|
| Carotid Artery, External | 1 | 2009 | 8 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 661 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 33 | 0.020 |
Why?
|
| Accidents, Occupational | 1 | 2009 | 8 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2010 | 86 | 0.020 |
Why?
|
| Cavernous Sinus | 1 | 2009 | 15 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 948 | 0.020 |
Why?
|
| Deep Brain Stimulation | 1 | 2010 | 62 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2010 | 125 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 894 | 0.020 |
Why?
|
| Steel | 1 | 1988 | 1 | 0.020 |
Why?
|
| Conjunctivitis, Acute Hemorrhagic | 1 | 1988 | 1 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 684 | 0.020 |
Why?
|
| Enterovirus | 1 | 1988 | 34 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 203 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 848 | 0.020 |
Why?
|
| Feces | 1 | 1989 | 327 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1401 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 780 | 0.020 |
Why?
|
| Cell Line | 2 | 1988 | 2495 | 0.020 |
Why?
|
| Radiology | 1 | 2009 | 199 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1533 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1940 | 0.020 |
Why?
|
| Skin | 1 | 1988 | 581 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2013 | 1041 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 3773 | 0.010 |
Why?
|
| Humidity | 1 | 1988 | 92 | 0.000 |
Why?
|
| Temperature | 1 | 1988 | 400 | 0.000 |
Why?
|
| Models, Biological | 1 | 1988 | 1764 | 0.000 |
Why?
|